Morgan Stanley analyst Jeffrey Hung upgraded PTC Therapeutics (PTCT) to Overweight from Equal Weight with a price target of $67, up from $45. The firm likes the setup for PTC shares heading into the new year following multiple recent positive updates, in contrast to the regulatory headwinds the company faced for nearly every program a little over a year ago. Heading into 2025, Morgan Stanley continues to believe that one of the main focuses for investors will be potential approval and launch of sepiapterin by the July 29 PDUFA date.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PTCT:
- Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics
- Biotech Alert: Searches spiking for these stocks today
- PTC Therapeutics price target raised to $32 from $26 at Citi
- PTC Therapeutics price target raised to $71 from $47 at UBS
- PTC Therapeutics price target raised to $70 from $52 at Baird
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
